D. Boral Capital Reiterates "Buy" Rating for Urogen Pharma (NASDAQ:URGN)

Key Points

• D. Boral Capital has reaffirmed a buy rating for Urogen Pharma, setting a price target of $25.00, which indicates a potential upside of 25.75% from the previous close.
• Urogen Pharma recently recorded a net loss of $0.92 earnings per share (EPS), falling short of analysts' estimates, with total revenue reported at $20.25 million.
• Insider sales were evident, with significant stock divestitures from executives, including a 3.15% decrease in ownership by Mark Schoenberg after selling over 5,149 shares.

D. Boral Capital reaffirmed their buy rating on shares of Urogen Pharma (NASDAQ:URGN - Free Report) in a report issued on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $25.00 price objective on the stock.

Other equities analysts have also issued research reports about the company. The Goldman Sachs Group set a $16.00 price objective on Urogen Pharma and gave the stock a "neutral" rating in a report on Friday, June 13th. Guggenheim reaffirmed a "buy" rating and issued a $30.00 price objective (up previously from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Urogen Pharma in a research report on Tuesday, July 8th. Scotiabank restated an "outperform" rating on shares of Urogen Pharma in a research report on Friday, June 13th. Finally, Oppenheimer set a $31.00 price target on Urogen Pharma and gave the company a "buy" rating in a report on Friday, June 13th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $32.86.

Urogen Pharma Stock Performance

Shares of URGN traded down $0.84 during midday trading on Tuesday, hitting $17.75. 1,177,783 shares of the stock were exchanged, compared to its average volume of 1,342,915. Urogen Pharma has a 52-week low of $3.42 and a 52-week high of $21.01. The stock has a fifty day simple moving average of $14.05 and a 200 day simple moving average of $11.34. The firm has a market cap of $820.05 million, a P/E ratio of -5.35 and a beta of 1.12.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.20). The firm had revenue of $24.22 million for the quarter, compared to analysts' expectations of $23.06 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%. As a group, equities research analysts forecast that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Insider Buying and Selling

In other Urogen Pharma news, General Counsel Jason Drew Smith sold 7,522 shares of Urogen Pharma stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $19.14, for a total transaction of $143,971.08. Following the transaction, the general counsel directly owned 41,492 shares in the company, valued at approximately $794,156.88. The trade was a 15.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Mark Schoenberg sold 5,149 shares of Urogen Pharma stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $19.14, for a total transaction of $98,551.86. Following the transaction, the insider owned 158,229 shares in the company, valued at approximately $3,028,503.06. The trade was a 3.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 17,833 shares of company stock valued at $280,567 over the last 90 days. 4.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Urogen Pharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Urogen Pharma by 4.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company's stock valued at $231,000 after purchasing an additional 969 shares during the last quarter. Wellington Management Group LLP raised its holdings in Urogen Pharma by 0.8% in the 1st quarter. Wellington Management Group LLP now owns 148,078 shares of the company's stock worth $1,638,000 after acquiring an additional 1,125 shares during the period. Rhumbline Advisers raised its holdings in Urogen Pharma by 4.3% in the 1st quarter. Rhumbline Advisers now owns 53,466 shares of the company's stock worth $591,000 after acquiring an additional 2,196 shares during the period. MetLife Investment Management LLC raised its holdings in Urogen Pharma by 13.6% in the 4th quarter. MetLife Investment Management LLC now owns 22,766 shares of the company's stock worth $242,000 after acquiring an additional 2,727 shares during the period. Finally, Legal & General Group Plc raised its holdings in Urogen Pharma by 24.6% in the 4th quarter. Legal & General Group Plc now owns 19,845 shares of the company's stock worth $211,000 after acquiring an additional 3,920 shares during the period. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.